US Stock MarketDetailed Quotes
NLSP NLS Pharmaceutics
- 0.1250
- -0.0052-3.99%
Close Apr 24 16:00 ET
- 0.1285
- +0.0035+2.80%
Post 18:54 ET
5.42MMarket Cap-250P/E (TTM)
0.1299High0.1201Low40.67KVolume0.1201Open0.1302Pre Close5.19KTurnover0.16%Turnover RatioLossP/E (Static)43.39MShares1.530052wk High-1.26P/B3.14MFloat Cap0.113052wk Low--Dividend TTM25.16MShs Float7.3500Historical High--Div YieldTTM7.53%Amplitude0.1130Historical Low0.1270Avg Price1Lot Size
About NLS Pharmaceutics Company
NLS Pharmaceutics AG engages in the discovery and development of drug therapies to treat rare and complex central nervous systems disorders. These disorders include narcolepsy, idiopathic hypersomnia and other rare sleep disorders, and of neurodevelopmental disorders, such as ADHD. The company was founded by Ronald Hafner and Alexander Zwyer in August 2015 and is headquartered in Stans, Switzerland.
Company Profile
SymbolNLSP
Company NameNLS Pharmaceutics
Listing DateJan 29, 2021
Issue Price4.15
Founded2015
CEOMr. Alexander Zwyer
MarketNASDAQ
Employees2
Securities TypeOrdinary Shares
Fiscal Year Ends12-31
AddressAlter Postplatz 2
CityStans
ProvinceNidwalden
CountrySwitzerland
Zip Code6370
Phone41-41-618-80-00
Websitehttp://nlspharma.com
Company Executives
- Name
- Position
- Salary
- Alexander Zwyer
- Chief Executive Officer and Director
- --
- Keith Harrison Dewedoff
- Interim Chief Financial Officer
- --
- George Apostol
- Chief Medical Officer and Global Head of Research and Development
- --
- Ronald Hafner
- Chairman of the Board
- --
- Myoung-Ok Kwon, PhD
- Independent Director
- --
- Stig Lokke Pedersen
- Independent Director
- --
- Gian-Marco Rinaldi
- Independent Director
- --
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg